Navigation Links
YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
Date:12/6/2010

Forty-eight (80%) had palpable splenomegaly greater than 10 cm. A number of the patients had discontinued treatment with other JAK inhibitors (INCB018424, n=11; TG101348, n=3) or pomalidomide (n=13). The median time to follow up since study start is currently 4.9 months, ranging from 0.9-12.5 months.

Efficacy Results: - The Overall Response Rate (anemia, spleen) to date, as per the International Working Group for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria, is 62%. - Anemia Response: Of 42 subjects who were evaluable for anemia response (baseline Hgb less than 10 g/dL or red cell transfusion- dependent), 21 subjects (50%) had achieved Clinical Improvement (CI) as per the IWG-MRT criteria. A 57% response rate was observed in transfusion dependent patients. For the 150 mg/day dosing group, the anemia response rate was 41% (43% for transfusion dependent patients). For the 300 mg/day dosing group, the anemia response rate was 58% (69% for transfusion dependent patients). Responses were observed in five of nine (55%) patients who had discontinued treatment with other JAK inhibitors (INCB018424, TG101348) and 5 of 12 (42%) who had discontinued pomalidomide. - Spleen Size Reduction: Twenty-five (47%) of the 53 evaluable subjects who had splenomegaly at baseline achieved a minimum 50% decrease in palpable spleen size, thus qualifying them for CI per IWG-MRT criteria. For the 150 mg/day dosing group, 53% qualified for CI. For the 300 mg/day dosing group, 46% qualified for CI. - Constitutional Symptoms: CYT387 controlled constitutional symptoms in a significant percentage of patients (night sweats: 88%, bone pain: 80%, pruritus: 92%, fever: 100%).

Safety Results:

In the dose escalation portion of the study, at the highest dose level (400 mg/day), two of six subjects experienced dose limiting toxicity (DLT) (one each of reversible asymptomatic Grade 3 hyperlipasemia and Grade 3 headache); consequently, the maximum tolerated
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387
2. Ardea Biosciences to Present at Two Upcoming Investor Conferences
3. YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
4. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
5. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
6. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
7. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
8. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
9. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
10. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
11. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... Q3 orders to $5.8 million and provides a good start to ... North America and one in the ... projects at record levels," said Peter Bruijns , President & ... end of Q3 than they have been for any complete year ...
(Date:10/20/2014)... Inc. (NASDAQ: GNVC ) today announced the retirement ... of directors effective on October 24, 2014.   Dr. Horovitz joined ... chairman from June 2006 to November 2013.  During his tenure, ... Audit Committees of the board.  "We deeply ... to GenVec, and its stockholders," said Wayne T. Hockmeyer ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Sidney Kimmel Cancer Center at Thomas Jefferson University ... , Through the Strategic Alliance Partnership program, the ... will collaborate to raise awareness of the Center’s ... and other projects. Clinicians and other health care ...
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy ... of donor stem cells for dogs with osteoarthritis. Dr. ... has performed clinical stem cell therapy for 7 years. ... if a single injection of donor stem cells into ... pain and inflammation in the treated joints. , ...
Breaking Biology Technology:Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... Today, at the Canadian,Diabetes Association Congress, physicians ... from a phase 3b clinical study (LEAD(TM) 6) ... study showed,that liraglutide, a human GLP-1 analog administered ... glucose control (as,measured by HbA1c) than exenatide, a ...
... researchers from Penn State and the University of Texas Southwestern ... control certain proteins that catalyze biochemical reactions. "This is ... activity of a protein using light," said Stephen Benkovic, Penn ... Family Chair in Chemistry, and one of the team,s leaders. ...
... 16 The Department of Biomedical,Engineering at ... Dr.,Michael Merzenich, one of the world,s premier ... speaker at the semi-annual Allen and,Constance Ford ... in,Cleveland. The program "A revolution in neuro-therapeutics: ...
Cached Biology Technology:New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 2New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 3New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 4Scientists use light to control proteins 2Brain and Hearing Pioneer, Michael Merzenich, Ph.D. to Speak at Case Western Reserve University 2Brain and Hearing Pioneer, Michael Merzenich, Ph.D. to Speak at Case Western Reserve University 3
(Date:10/17/2014)... in German . ... day in order to reproduce? And why are there two ... the latest issue of the research journal Molecular Human ... Steven Ramm from Bielefeld University Bielefeld has compiled this special ... for a female to copulate with several males in quick ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
Breaking Biology News(10 mins):Sperm wars 2Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2
... Most venomous snakes are legendary for their lethal bites, ... University of Massachusetts Lowell, explains that some cobras defend themselves ... Getting the chance to work with spitting cobras in South ... tracks aimed at his eyes. Protected by a sheet of ...
... Texas May 14, 2010 Scientists studying the ... of Louisiana and the city of New Orleans have ... exposure to chemical contaminants. The findings, published in a ... demonstrate how Hurricane Katrina caused significant ecological damage by ...
... 2010) Novel vaccines for diseases ranging from the ... research at the American Association of Pharmaceutical Scientists, (AAPS) ... government will gather at the Hilton San Francisco Union ... research and advances in biotherapeutics. Researchers from ...
Cached Biology News:Spitting cobras track first, predict later 2New research reveals Hurricane Katrina's impact on ecological and human health 2New research reveals Hurricane Katrina's impact on ecological and human health 3Cutting-edge vaccine research to be showcased at AAPS National Biotechnology Conference 2
EPA II Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... important role in the regulation of signaling ... Splice variants have been reported that affect ... apoptotic pathways. With Apoptosis and Cell Death ... expression profiling and at the same time ...
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
... Kit is manufactured for DNA purification from ... to UV light. The Purification of DNA ... for DNA-cloning work. The conventional method of ... of UV light damages DNA and significantly ...
Biology Products: